Camilla Simpson

Camilla Simpson has over 25 years of business and strategy experience across a diverse group of organizations: from seed investments to public companies. Camilla has a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need. Currently, Camilla is CEO of Zehna Therapeutics, Inc., a seed stage startup and academic spin out of the Cleveland Clinic. Prior to Zehna, Camilla founded Rare Strategic LLC where she provided strategic advice to early stage venture-backed companies. Camilla has held numerous executive leadership positions, including SVP, Head of Product Portfolio Development at BioMarin Pharmaceutical Inc., Global Head of Regulatory Affairs at BioMarin Pharmaceutical Inc., and VP Global Regulatory Strategy- Early Development and Business Development at Shire Pharmaceuticals. Camilla is a board member of Spruce Biosciences, a public company, and Dyve Biosciences, a private company.